SAN FRANCISCO (GenomeWeb News) — Financial cutbacks, under-trained and overworked reviewers, widespread risk aversion, and eroding morale at the US Food and Drug Administration are hurting the agency’s ability to effectively review new drugs, according to a prominent regulatory lawyer.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

NPR reports that with medical data being big business, some companies want to get patients involved.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.